Allergan (AGN) Tops Q1 EPS by 24c, Offers Q2 and Updated FY Guidance

Allergan (NYSE: AGN) reported Q1 EPS of $3.79, $0.24 better than the analyst estimate of $3.55. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.54 billion.

GUIDANCE:

Allergan sees FY2019 EPS of $16.55, versus the consensus of $16.43. Allergan sees FY2019 revenue of $15.1-15.4 billion, versus the consensus of $15.2 billion.

Allergan sees Q2 2019 EPS of $4.20-$4.40, versus the consensus of $4.20. Allergan sees Q2 2019 revenue of $3.85-4 billion, versus the consensus of $3.87 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c